Soliqua 100/33 for the Treatment of Type 2 Diabetes

Developed by Sanofi, Soliqua 100/33 (insulin glargine& Lixisenatide injection) is indicated for the treatment of Type 2 diabetes.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news